Seth Klarman’s Top Holdings, Trades & Investment Strategy
Baupost Group reported a $5.12 billion equity portfolio, with the top ten holdings representing roughly 74% of assets, underscoring a highly concentrated approach. The firm boosted its Amazon stake by 47% and added sizable positions in Aon, Visa and Teleflex, while trimming several fintech and retail names. Core holdings span technology, industrial, consumer, healthcare and financial businesses, reflecting Klarman’s blend of growth‑oriented platforms and defensive franchises. Overall, the filing signals a measured, value‑focused rebalancing rather than a sweeping overhaul.
Merck & Co. (MRK): Our Calculation of Intrinsic Value
Merck & Co.’s discounted cash‑flow model values the stock at $96‑98 per share, roughly 14% below its current $113 market price. The analysis assumes an 8% discount rate and 2% terminal growth, projecting free cash flow of $15‑18 billion from 2026...
Undervalued LNG Carrier: Dynagas LNG Partners LP (DLNG)
Dynagas LNG Partners LP (DLNG) operates a fleet of ice‑class LNG carriers under long‑term fixed‑rate charters, delivering predictable cash flow despite the cyclical shipping market. The company reports $156.6 million in revenue, $50.4 million net income and $90.3 million free cash flow for...
This Week’s Deep-Value Landscape: Acquirer’s Multiple Large-Cap Screen
The Acquirer’s Multiple® Large‑Cap screen this week spotlights a broad set of mature, cash‑generating companies that trade at deep discounts relative to their current earnings strength. Financials such as Synchrony Financial, energy majors like Equinor and BP, and cyclical firms...
Home Depot (HD): Our Calculation of Intrinsic Value
Home Depot’s discounted cash‑flow model yields an intrinsic share price of roughly $235‑$240, well below its current trading level near $329. The analysis assumes an 8% discount rate, 3% terminal growth and projects free cash flow climbing to $17 billion by...
Deeply Undervalued Global Medical Device Company – Embecta Corp. (EMBC)
Embecta Corp. (EMBC) is a global diabetes‑care device maker trading at an IV/P of 1.90 and an Acquirer’s Multiple of 5.03, suggesting significant undervaluation. The company posted $1.08 billion in revenue, $140 million net income and $206 million free cash flow, while maintaining...
Howard Marks: You Can’t Predict. You Can Prepare
Howard Marks told Nikhil Kamath that market cycles are driven by behavior, not fundamentals, and that trying to predict exact outcomes is futile. He warns that AI enthusiasm and massive passive inflows keep valuations high despite hidden risks, but classic...
Smart Money Is Buying Darling Ingredients Inc. (DAR)
Institutional investors are increasing stakes in Darling Ingredients Inc. (DAR) after the latest 13F filings, with Point72 Asset Management leading the charge by adding 1.84 million shares. Deep‑value and quantitative managers such as AQR, Davis Selected Advisers, and GMO also expanded...
Rich Pzena’s Latest Portfolio & Strategy Explained
Pzena Investment Management reported a $30.8 billion equity portfolio for the latest quarter, with the top ten holdings accounting for about 35.7% of assets. The firm’s deep‑value strategy targets out‑of‑favor companies across cyclical, financial, healthcare and industrial sectors, while maintaining moderate...
Why Paul Tudor Jones Calls Warren Buffett the OG of Compound Interest
Paul Tudor Jones, famed macro trader, praised Warren Buffett as the original master of compounding during a recent Invest Like The Best interview. Jones admitted he once dismissed Buffett’s success as luck, but now acknowledges the power of Berkshire Hathaway’s...
Nick Train Portfolio Update: Top Holdings, Latest Buys & Stock Moves
Lindsell Train Ltd reported a $3.14 billion equity portfolio, with the top ten holdings accounting for nearly 94% of assets. The core positions include Alphabet, Intuit, Disney, Thermo Fisher, FICO, Mondelez, PepsiCo, PayPal and eBay, reflecting a blend of consumer brands and...
Mohnish Pabrai’s SXSW 2026 Investing Lessons Every Investor Should Know
At SXSW 2026, investor Mohnish Pabrai urged a return to disciplined simplicity, arguing that execution and temperament outweigh complex forecasts. He highlighted how incremental gains compound exponentially when backed by trust, culture, and patient capital. Pabrai also championed asymmetric bets,...
Johnson & Johnson (JNJ): Our Calculation of Intrinsic Value
Johnson & Johnson’s latest discounted cash flow model values the stock at $165‑170 per share, well below its roughly $240 market price, implying a roughly 30% overvaluation. The analysis incorporates an 8% discount rate, 3% terminal growth, and projects free...
BellRing Brands, Inc. (BRBR): Deeply Undervalued Fast-Growing Branded Nutrition Company
BellRing Brands, Inc. (BRBR) is a fast‑growing consumer packaged goods company that sells premium protein shakes, powders and nutrition bars under brands like Premier Protein and Dymatize. The firm posted $2.32 billion of revenue last twelve months, generating $250 million+ of free...
Jeremy Grantham’s Latest Market Outlook: Valuations, Risk and Opportunity
Jeremy Grantham, co‑founder of GMO, emphasized that valuation remains the decisive factor in investing, even when market momentum appears unstoppable. In a recent Master Investor Podcast interview, he urged investors to exit clearly overpriced stocks and concentrate on assets with...